Selected research
Industry Research
Gemcitabine Hydrochloride API Industry Research Report 2026
Market perspective
The global Gemcitabine Hydrochloride API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gemcitabine Hydrochloride API is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gemcitabine Hydrochloride API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gemcitabine Hydrochloride API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gemcitabine Hydrochloride API include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gemcitabine Hydrochloride API market in revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Gemcitabine Hydrochloride API.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gemcitabine Hydrochloride API Market by Company
Zhejiang Hisun Pharmaceutical
Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical
Shanghai Chuangnuo Pharmaceutical
Shandong Anhong Pharmaceutical
Fu'an Pharmaceutical Group
Hubei Bantian Pharmaceutical
Jiangsu Hansoh Pharmaceutical Group
Jiangsu Zhengda Qingjiang Pharmaceutical
Lianyungang Jerry Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Lianyungang Runzhong Pharmaceutical
Sanofi
Gemcitabine Hydrochloride API Segment by Type
0.98
0.99
Others
Gemcitabine Hydrochloride API Segment by Application
Pharmaceutical
Research
Gemcitabine Hydrochloride API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gemcitabine Hydrochloride API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gemcitabine Hydrochloride API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gemcitabine Hydrochloride API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gemcitabine Hydrochloride API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gemcitabine Hydrochloride API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gemcitabine Hydrochloride API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.98
- 0.99
- Others
Applications
- Pharmaceutical
- Research
Companies covered
- Zhejiang Hisun Pharmaceutical
- Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical
- Shanghai Chuangnuo Pharmaceutical
- Shandong Anhong Pharmaceutical
- Fu'an Pharmaceutical Group
- Hubei Bantian Pharmaceutical
- Jiangsu Hansoh Pharmaceutical Group
- Jiangsu Zhengda Qingjiang Pharmaceutical
- Lianyungang Jerry Pharmaceutical
- Shandong Luoxin Pharmaceutical Group
- Lianyungang Runzhong Pharmaceutical
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gemcitabine Hydrochloride API by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 0.98
- 2.2.3 0.99
- 2.2.4 Others
- 2.3 Gemcitabine Hydrochloride API by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pharmaceutical
- 2.3.3 Research
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Gemcitabine Hydrochloride API Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Gemcitabine Hydrochloride API Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Gemcitabine Hydrochloride API Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Gemcitabine Hydrochloride API Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gemcitabine Hydrochloride API Production by Manufacturers (2021-2026)
- 3.2 Global Gemcitabine Hydrochloride API Production Value by Manufacturers (2021-2026)
- 3.3 Global Gemcitabine Hydrochloride API Average Price by Manufacturers (2021-2026)
- 3.4 Global Gemcitabine Hydrochloride API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Gemcitabine Hydrochloride API Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Gemcitabine Hydrochloride API Manufacturers, Product Type & Application
- 3.7 Global Gemcitabine Hydrochloride API Manufacturers Established Date
- 3.8 Global Gemcitabine Hydrochloride API Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zhejiang Hisun Pharmaceutical
- 4.1.1 Zhejiang Hisun Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.1.2 Zhejiang Hisun Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.1.3 Zhejiang Hisun Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 Zhejiang Hisun Pharmaceutical Product Portfolio
- 4.1.5 Zhejiang Hisun Pharmaceutical Recent Developments
- 4.2 Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical
- 4.2.1 Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.2.2 Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.2.3 Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Product Portfolio
- 4.2.5 Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Recent Developments
- 4.3 Shanghai Chuangnuo Pharmaceutical
- 4.3.1 Shanghai Chuangnuo Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.3.2 Shanghai Chuangnuo Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.3.3 Shanghai Chuangnuo Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Shanghai Chuangnuo Pharmaceutical Product Portfolio
- 4.3.5 Shanghai Chuangnuo Pharmaceutical Recent Developments
- 4.4 Shandong Anhong Pharmaceutical
- 4.4.1 Shandong Anhong Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.4.2 Shandong Anhong Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.4.3 Shandong Anhong Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 Shandong Anhong Pharmaceutical Product Portfolio
- 4.4.5 Shandong Anhong Pharmaceutical Recent Developments
- 4.5 Fu'an Pharmaceutical Group
- 4.5.1 Fu'an Pharmaceutical Group Gemcitabine Hydrochloride API Company Information
- 4.5.2 Fu'an Pharmaceutical Group Gemcitabine Hydrochloride API Business Overview
- 4.5.3 Fu'an Pharmaceutical Group Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 Fu'an Pharmaceutical Group Product Portfolio
- 4.5.5 Fu'an Pharmaceutical Group Recent Developments
- 4.6 Hubei Bantian Pharmaceutical
- 4.6.1 Hubei Bantian Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.6.2 Hubei Bantian Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.6.3 Hubei Bantian Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 Hubei Bantian Pharmaceutical Product Portfolio
- 4.6.5 Hubei Bantian Pharmaceutical Recent Developments
- 4.7 Jiangsu Hansoh Pharmaceutical Group
- 4.7.1 Jiangsu Hansoh Pharmaceutical Group Gemcitabine Hydrochloride API Company Information
- 4.7.2 Jiangsu Hansoh Pharmaceutical Group Gemcitabine Hydrochloride API Business Overview
- 4.7.3 Jiangsu Hansoh Pharmaceutical Group Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 Jiangsu Hansoh Pharmaceutical Group Product Portfolio
- 4.7.5 Jiangsu Hansoh Pharmaceutical Group Recent Developments
- 4.8 Jiangsu Zhengda Qingjiang Pharmaceutical
- 4.8.1 Jiangsu Zhengda Qingjiang Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.8.2 Jiangsu Zhengda Qingjiang Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.8.3 Jiangsu Zhengda Qingjiang Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 Jiangsu Zhengda Qingjiang Pharmaceutical Product Portfolio
- 4.8.5 Jiangsu Zhengda Qingjiang Pharmaceutical Recent Developments
- 4.9 Lianyungang Jerry Pharmaceutical
- 4.9.1 Lianyungang Jerry Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.9.2 Lianyungang Jerry Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.9.3 Lianyungang Jerry Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 Lianyungang Jerry Pharmaceutical Product Portfolio
- 4.9.5 Lianyungang Jerry Pharmaceutical Recent Developments
- 4.10 Shandong Luoxin Pharmaceutical Group
- 4.10.1 Shandong Luoxin Pharmaceutical Group Gemcitabine Hydrochloride API Company Information
- 4.10.2 Shandong Luoxin Pharmaceutical Group Gemcitabine Hydrochloride API Business Overview
- 4.10.3 Shandong Luoxin Pharmaceutical Group Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.10.4 Shandong Luoxin Pharmaceutical Group Product Portfolio
- 4.10.5 Shandong Luoxin Pharmaceutical Group Recent Developments
- 4.11 Lianyungang Runzhong Pharmaceutical
- 4.11.1 Lianyungang Runzhong Pharmaceutical Gemcitabine Hydrochloride API Company Information
- 4.11.2 Lianyungang Runzhong Pharmaceutical Gemcitabine Hydrochloride API Business Overview
- 4.11.3 Lianyungang Runzhong Pharmaceutical Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.11.4 Lianyungang Runzhong Pharmaceutical Product Portfolio
- 4.11.5 Lianyungang Runzhong Pharmaceutical Recent Developments
- 4.12 Sanofi
- 4.12.1 Sanofi Gemcitabine Hydrochloride API Company Information
- 4.12.2 Sanofi Gemcitabine Hydrochloride API Business Overview
- 4.12.3 Sanofi Gemcitabine Hydrochloride API Production Capacity, Value and Gross Margin (2021-2026)
- 4.12.4 Sanofi Product Portfolio
- 4.12.5 Sanofi Recent Developments
5 Global Gemcitabine Hydrochloride API Production by Region
- 5.1 Global Gemcitabine Hydrochloride API Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gemcitabine Hydrochloride API Production by Region: 2021-2032
- 5.2.1 Global Gemcitabine Hydrochloride API Production by Region: 2021-2026
- 5.2.2 Global Gemcitabine Hydrochloride API Production Forecast by Region (2027-2032)
- 5.3 Global Gemcitabine Hydrochloride API Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Gemcitabine Hydrochloride API Production Value by Region: 2021-2032
- 5.4.1 Global Gemcitabine Hydrochloride API Production Value by Region: 2021-2026
- 5.4.2 Global Gemcitabine Hydrochloride API Production Value Forecast by Region (2027-2032)
- 5.5 Global Gemcitabine Hydrochloride API Market Price Analysis by Region (2021-2026)
- 5.6 Global Gemcitabine Hydrochloride API Production and Value, YOY Growth
- 5.6.1 North America Gemcitabine Hydrochloride API Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Gemcitabine Hydrochloride API Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Gemcitabine Hydrochloride API Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Gemcitabine Hydrochloride API Production Value Estimates and Forecasts (2021-2032)
6 Global Gemcitabine Hydrochloride API Consumption by Region
- 6.1 Global Gemcitabine Hydrochloride API Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gemcitabine Hydrochloride API Consumption by Region (2021-2032)
- 6.2.1 Global Gemcitabine Hydrochloride API Consumption by Region: 2021-2026
- 6.2.2 Global Gemcitabine Hydrochloride API Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Gemcitabine Hydrochloride API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Gemcitabine Hydrochloride API Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Gemcitabine Hydrochloride API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Gemcitabine Hydrochloride API Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Gemcitabine Hydrochloride API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Gemcitabine Hydrochloride API Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Gemcitabine Hydrochloride API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Gemcitabine Hydrochloride API Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Gemcitabine Hydrochloride API Production by Type (2021-2032)
- 7.1.1 Global Gemcitabine Hydrochloride API Production by Type (2021-2032) & (Tons)
- 7.1.2 Global Gemcitabine Hydrochloride API Production Market Share by Type (2021-2032)
- 7.2 Global Gemcitabine Hydrochloride API Production Value by Type (2021-2032)
- 7.2.1 Global Gemcitabine Hydrochloride API Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Gemcitabine Hydrochloride API Production Value Market Share by Type (2021-2032)
- 7.3 Global Gemcitabine Hydrochloride API Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Gemcitabine Hydrochloride API Production by Application (2021-2032)
- 8.1.1 Global Gemcitabine Hydrochloride API Production by Application (2021-2032) & (Tons)
- 8.1.2 Global Gemcitabine Hydrochloride API Production Market Share by Application (2021-2032)
- 8.2 Global Gemcitabine Hydrochloride API Production Value by Application (2021-2032)
- 8.2.1 Global Gemcitabine Hydrochloride API Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Gemcitabine Hydrochloride API Production Value Market Share by Application (2021-2032)
- 8.3 Global Gemcitabine Hydrochloride API Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Gemcitabine Hydrochloride API Value Chain Analysis
- 9.1.1 Gemcitabine Hydrochloride API Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Gemcitabine Hydrochloride API Production Mode & Process
- 9.2 Gemcitabine Hydrochloride API Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gemcitabine Hydrochloride API Distributors
- 9.2.3 Gemcitabine Hydrochloride API Customers
10 Global Gemcitabine Hydrochloride API Analyzing Market Dynamics
- 10.1 Gemcitabine Hydrochloride API Industry Trends
- 10.2 Gemcitabine Hydrochloride API Industry Drivers
- 10.3 Gemcitabine Hydrochloride API Industry Opportunities and Challenges
- 10.4 Gemcitabine Hydrochloride API Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst